New York · Series A–Late Stage · 17 people tracked
Also known as BLACKSTONE ALTERNATIVE ASSET MANAGEMENT L.P. · BLACKSTONE ALTERNATIVE CREDIT ADVISORS LP · BLACKSTONE ALTERNATIVE INVESTMENT ADVISORS LLC · BLACKSTONE ALTERNATIVE SOLUTIONS L.L.C. · BLACKSTONE ASSET BASED FINANCE ADVISORS LP · BLACKSTONE CLO MANAGEMENT LLC (MANAGEMENT SERIES) · BLACKSTONE CREDIT BDC ADVISORS LLC · BLACKSTONE CREDIT SYSTEMATIC STRATEGIES LLC · BLACKSTONE EUROPE FUND MANAGEMENT S.A.R.L. · BLACKSTONE GROWTH ADVISORS L.L.C. · BLACKSTONE INFRASTRUCTURE ADVISORS L.L.C. · BLACKSTONE IRELAND FUND MANAGEMENT LIMITED · BLACKSTONE IRELAND LIMITED · BLACKSTONE ISG-I ADVISORS L.L.C. · BLACKSTONE ISG-II ADVISORS L.L.C. · BLACKSTONE LIQUID CREDIT ADVISORS I LLC · BLACKSTONE LIQUID CREDIT STRATEGIES LLC · BLACKSTONE MANAGEMENT PARTNERS L.L.C. · BLACKSTONE MULTI-ASSET ADVISORS L.L.C. · BLACKSTONE PRIVATE CREDIT STRATEGIES LLC · BLACKSTONE PRIVATE INVESTMENTS ADVISORS L.L.C. · BLACKSTONE PROPERTY ADVISORS L.P. · BLACKSTONE REAL ESTATE ADVISORS EUROPE L.P. · BLACKSTONE REAL ESTATE ADVISORS L.P. · BLACKSTONE REAL ESTATE ADVISORS V L.P. · BLACKSTONE REAL ESTATE SPECIAL SITUATIONS ADVISORS L.L.C. · BLACKSTONE STRATEGIC ALLIANCE ADVISORS L.L.C. · BLACKSTONE STRATEGIC CAPITAL ADVISORS, L.L.C. · BLACKSTONE TACTICAL OPPORTUNITIES ADVISORS L.L.C. · BX REIT ADVISORS L.L.C. · BXMT ADVISORS L.L.C. · CLARUS VENTURES, LLC · CLOVER CREDIT MANAGEMENT, LLC · CT INVESTMENT MANAGEMENT CO., LLC · HARVEST FUND ADVISORS LLC · STRATEGIC PARTNERS FUND SOLUTIONS ADVISORS L.P.
Investment thesis
BXLS collaborates with leading pharmaceutical, biotech and medical technology companies to fund and advance late-stage clinical development of critical-path products addressing unmet medical needs. It combines clinical, commercial and operational expertise with Blackstone's global network, capital access and infrastructure to select and advance promising products and companies. The strategy aims to fill a funding gap between the demand for development capital and what pharma and MedTech R&D budgets can supply. BXLS seeks attractive, largely market- and interest-rate-uncorrelated returns at lower risk by capturing value directly from the products it funds rather than through equity exposure, sometimes forming and growing companies around promising clinical assets.
Source: firm website, verified Aug 25, 2026.
Team · 17 people
from curated & public directories
What they invest in
from 4 of 5 portfolio companiesBiotech ×3Medical Devices ×3Deep Tech ×1Digital Health ×1Enterprise Software ×1Healthtech ×1InsurTech ×1Longevity ×1
HQs:United States×1
Investments · 5 tracked
founders shown can be your intro pathBy year:2026 · 12024 · 12016 · 13 dated
AvenCell Therapeutics develops next-generation cell therapies for hard-to-treat cancers, including solid tumors, combining switchable universal CAR-T technology with a CRISPR/Cas9-based allogeneic platform.
BiotechLongevityMedical Devices
Andrew Schiermeier(Chief Executive Officer)in
Co-investorsNovo HoldingsEight Roads VenturesF-Prime CapitalNYBC Ventures
Alnylam is a biopharmaceutical company that supports investigator-initiated studies in therapeutic areas including transthyretin-mediated amyloidosis, acute hepatic porphyria, and primary hyperoxaluria for medical researchers and healthcare professionals.
BiotechDigital HealthMedical Devices
John Maraganore(Founder)inDr. Yvonne Greenstreetin
Co-investorsARCH Venture PartnersAtlas VentureCardinal Partners
Anagram builds software to help eye care providers manage vision insurance, lab ordering, and administrative workflows so they can deliver better patient care affordably.
Enterprise SoftwareHealthtechInsurTechSaaS
Co-investorsGreatPoint VenturesHealthy VenturesManchesterStory Group, LLCKEC VenturesKickstartNextView Ventures+1 more
Founded by BXLS with Novartis in February 2019 to advance next-generation targeted therapies for high-risk cardiovascular patients; sold to Novartis in April 2025.
Moderna develops mRNA-based medicines for infectious and serious diseases using its proprietary mRNA platform and design technology.
BiotechDeep TechMedical DevicesCambridge, US
Robert Langer(Director)Lorence Kim(Executive Officer)James R. Kasinger(Executive Officer)Stephen Hoge(Executive Officer)in
BoardStephane Bancel(Executive Officer, Director)John Mendlein(Director)
Co-investorsAglae VenturesFlagship PioneeringFPVKhosla VenturesPremji InvestRA Capital
Portfolio news
latest coverage across their companiesModerna · forbes.com · Jul 19, 2026
Alnylam · tipranks.com · Jul 17, 2026
Frequently asked questions
- What stage does Blackstone Life Sciences invest at?
- Blackstone Life Sciences invests at the Series A, Series B, Series C, Growth, Late Stage stages.
- What is Blackstone Life Sciences's typical check size?
- Blackstone Life Sciences typically writes checks of $20M – $60M.
- What sectors does Blackstone Life Sciences focus on?
- Blackstone Life Sciences focuses on Biotech, Crypto & Web3, Digital Health, Healthtech, Longevity, Medical Devices, Sector Agnostic.
- Where is Blackstone Life Sciences located?
- Blackstone Life Sciences is headquartered in New York, US.
- Who does Blackstone Life Sciences co-invest with?
- Blackstone Life Sciences most often shares deals with ARCH Venture Partners, Atlas Venture, Cardinal Partners, among 9 tracked co-investors.
Images
Similar investors
Khosla Ventures is a venture capital firm founded by Vinod Khosla.
NJF Capital is the venture investment arm of NJF Holdings, the private investment group founded by Nicole Junkermann. It backs transformative entrepreneurs building industry-defining technologies with global scale potential.
GV (Google Ventures) is a venture capital firm that has invested in artificial intelligence and machine learning since its early days, building a global portfolio of more than 100 AI companies across infrastructure, life sciences, and applications.
A globally recognized venture capital firm designed to provide access to highly competitive venture deals to individual investors, consistently recognized for top-decile DPI performance and as one of the most active US venture firms.
EQT Life Sciences, formerly LSP, is one of Europe's largest and most experienced life sciences investors, backing companies developing therapeutics, medical devices, diagnostics and healthtech globally. It is part of EQT Group.